Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease.


Journal Article

Prior studies have shown that overexpression of HER-2/neu occurs in one third of breast and ovarian cancers and that overexpression is associated with poor prognosis. We used a monoclonal antibody to assess immunohistochemically the level of HER-2/neu expression in normal and malignant endometrium. In 24 normal endometrial samples light to moderate (1+ to 2+) staining for HER-2/neu was seen in the glands, and there was no variation in intensity of staining during the menstrual cycle. Among 95 endometrial adenocarcinomas, nine (9%) were found to have heavier staining for HER-2/neu than was seen in normal endometrium (3+). High expression of HER-2/neu was found in 27% of patients with metastatic disease compared with 4% of patients with disease confined to the uterus (p less than 0.005). High HER-2/neu expression also was associated with absence of estrogen receptor (p less than 0.005) and with increased mortality from cancer. Further studies are needed to determine the significance of HER-2/neu overexpression in endometrial cancer.

Full Text

Duke Authors

Cited Authors

  • Berchuck, A; Rodriguez, G; Kinney, RB; Soper, JT; Dodge, RK; Clarke-Pearson, DL; Bast, RC

Published Date

  • January 1, 1991

Published In

Volume / Issue

  • 164 / 1 Pt 1

Start / End Page

  • 15 - 21

PubMed ID

  • 1670908

Pubmed Central ID

  • 1670908

International Standard Serial Number (ISSN)

  • 0002-9378

Digital Object Identifier (DOI)

  • 10.1016/0002-9378(91)90615-x


  • eng

Conference Location

  • United States